PAPILLARY RENAL CELL CARCINOMA
Clinical trials for PAPILLARY RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PAPILLARY RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for PAPILLARY RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo aims to ease bone pain in advanced kidney cancer
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 participants will receive either the combination or cabozantinib alone. The goal is to see if the …
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare kidney cancer: drug combo shows promise in late-stage trial
Disease control OngoingThis phase 3 study tests whether combining two drugs (savolitinib and durvalumab) works better than the standard drug sunitinib for people with a rare, advanced kidney cancer called papillary renal cell carcinoma that has a specific genetic change (MET-driven). About 148 adults w…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo shows promise for rare kidney cancers
Disease control OngoingThis study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is …
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Hao Zeng • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Triple-Drug cocktail shows promise for rare kidney cancers
Disease control OngoingThis study tests whether combining three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow or shrink advanced kidney cancers that are not the common clear-cell type. About 60 adults with cancers like papillary or chromophobe RCC that have spread will receive the com…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Bradley A. McGregor, MD • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Head-to-Head drug battle for rare kidney cancer
Disease control OngoingThis study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at slowing cancer growth. About 32 to 84 participa…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo shows promise for tough kidney cancers
Disease control OngoingThis study tests two drugs, nivolumab and cabozantinib, together in 60 people with advanced or metastatic non-clear cell kidney cancer. The goal is to see how well the combination shrinks tumors. Participants take cabozantinib daily and receive nivolumab infusions every two weeks…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC